Suppr超能文献

牛津疫苗技术评级基准量表(OBSRVT)的开发与验证,该量表用于评估公众对下一代疫苗接种技术的态度。

Development and validation of the Oxford Benchmark Scale for Rating Vaccine Technologies (OBSRVT), a scale for assessing public attitudes to next-generation vaccine delivery technologies.

作者信息

Kantor Jonathan, Carlisle Robert C, Vanderslott Samantha, Pollard Andrew J, Morrison Michael

机构信息

Oxford Vaccine Group, University of Oxford, Oxford, UK.

Biomedical Ultrasonics, Biotherapy, and Biopharmaceuticals Laboratory (BUBBL), Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.

出版信息

Hum Vaccin Immunother. 2025 Dec;21(1):2469994. doi: 10.1080/21645515.2025.2469994. Epub 2025 Mar 3.

Abstract

Next-generation vaccine delivery technologies may provide significant gains from both a technical and behavioral standpoint, but no scale has yet been developed to assess public attitudes to novel vaccine delivery technologies. We therefore performed a cross-sectional validation study that included 1,001 demographically representative participants from the UK and US to develop and validate a novel scale, the Oxford Benchmark Scale for Rating Vaccine Technologies (OBSRVT). A sample of 500 UK participants was used to perform exploratory factor analysis with categorical variables (using a polychoric correlation matrix) followed by promax oblique factor rotation to develop the initial model. This yielded a 15-item 4-domain scale with domains including acceptance (6 items), effectiveness (4 items), comfort (3 items), and convenience (2 items). This model was tested for robustness on a 501-participant demographically representative sample from the US. A confirmatory factor analysis with a Satorra-Bentler scaled test statistic was performed, which demonstrated adequate goodness of fit statistics including the root mean squared error of approximation (0.057), standardized root mean squared residual (0.053), and comparative fit index (0.938). Reliability as internal consistency was excellent (alpha = 0.92). Convergent validity with the Oxford Needle Experience Scale was supported by an adequate correlation ( = 0.31,  < .0001), while discriminant validity was supported by a lack of correlation with an unrelated question ( = -0.03,  < .0001). These findings suggest that the OBSRVT scale represents a feasible, valid, and reliable scale that could be used to gauge the acceptability of existing and future vaccine delivery technologies, and further investigation and testing should be considered.

摘要

从技术和行为角度来看,下一代疫苗递送技术可能会带来显著收益,但尚未开发出用于评估公众对新型疫苗递送技术态度的量表。因此,我们进行了一项横断面验证研究,纳入了来自英国和美国的1001名具有人口统计学代表性的参与者,以开发和验证一种新型量表——牛津疫苗技术评级基准量表(OBSRVT)。我们使用500名英国参与者的样本,对分类变量进行探索性因素分析(使用多相关矩阵),然后进行promax斜交因素旋转以建立初始模型。这产生了一个包含15个条目的4个维度的量表,维度包括接受度(6个条目)、有效性(4个条目)、舒适度(3个条目)和便利性(2个条目)。我们在美国501名具有人口统计学代表性的样本上对该模型进行了稳健性测试。进行了带有Satorra - Bentler缩放检验统计量的验证性因素分析,结果显示拟合优度统计量良好,包括近似均方根误差(0.057)、标准化均方根残差(0.053)和比较拟合指数(0.938)。内部一致性的信度非常好(α = 0.92)。与牛津针头体验量表的收敛效度得到了充分相关性(r = 0.31,p <.0001)的支持,而区分效度则得到了与一个不相关问题缺乏相关性(r = -0.03,p <.0001)的支持。这些发现表明,OBSRVT量表是一个可行、有效且可靠的量表,可用于衡量现有和未来疫苗递送技术的可接受性,应考虑进一步的调查和测试。

相似文献

8
Cross-cultural adaptation and validation of an Urdu version of the Vaccine Attitudes Examination (VAX-U) scale.
PLoS One. 2024 Oct 25;19(10):e0312459. doi: 10.1371/journal.pone.0312459. eCollection 2024.

本文引用的文献

3
Predictors of parental acceptance to live attenuated influenza vaccine for children.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2356343. doi: 10.1080/21645515.2024.2356343. Epub 2024 Jun 4.
4
Ethical Challenges of Advances in Vaccine Delivery Technologies.
Hastings Cent Rep. 2024 Jan;54(1):13-15. doi: 10.1002/hast.1563.
6
7
Evaluation of the self-administration potential of high-density microarray patches to human skin: A preliminary study.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2189409. doi: 10.1080/21645515.2023.2189409. Epub 2023 Mar 22.
9
Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication.
Hum Vaccin Immunother. 2022 Dec 30;18(7):2154100. doi: 10.1080/21645515.2022.2154100. Epub 2022 Dec 28.
10
Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer's perspective.
Hum Vaccin Immunother. 2022 Nov 30;18(4):2050123. doi: 10.1080/21645515.2022.2050123. Epub 2022 Mar 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验